Remicaide for CVHD – pro
Only case reports and series leeve evidence is available. Infliximab was found to be effective in the treatment of gastrointestinal manifestations of refractory acute and chronic GVHD, with three out of four patients responding in one report. In a retrospective analysis of 22 patients refractory to tacrolimus/cyclosporine and systemic steroids the overall response rate was 64% (n=14); 11 (50%) experienced a complete response (CR); 3 (14%) experienced a partial response (PR); 8 (36%) had progressive GVHD. Another retrospective analysis found that it as effective, but produced a higher rate of infectinon and called for controlled studies.
Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, Martin P, Chien J, Przepiorka D, Couriel D, Cowen EW, Dinndorf P, Farrell A, Hartzman R, Henslee-Downey J, Jacobsohn D, McDonald G, Mittleman B, Rizzo JD, Robinson M, Schubert M, Schultz K, Shulman H, Turner M, Vogelsang G, Flowers ME. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005 Dec;11(12):945-56.
Ethan Tolbert, Ned Waller, H. Jean Khoury, Mary Jo Lechowicz, Christopher Flowers, Sagar Lonial, Laura Vann, Amelia Langston and Jonathan L. Kaufman,
Infliximab for the Treatment of Chronic Graft Versus Host Disease.Blood 2006 108:2889;
Kazuya Ishiwata, Aya Nishida, Hikari Ota, Taichi Ikebe, Masanori Tsuji, Hisashi Yamamoto, Yuki Asano-Mori, Naoyuki Uchida, Koji Izutsu and Shuichi , TaniguchiInfliximab Treatment for Steroid-Refractory Acute Graft-Versus-Host Disease After Reduced-Intensity Cord Blood Transplantation in Adults
Blood 2011 118:4553
Revlimid, Prescribing Information, 2018
British Soc for Blood and Marrow transplantation, https://www.guidelinecentral.com/summaries/diagnosis-and-management-of-acute-graft-versus-host-disease/#section-society, 2018